G
Guy E.H.M. Rutten
Researcher at University Medical Center Utrecht
Publications - 224
Citations - 11779
Guy E.H.M. Rutten is an academic researcher from University Medical Center Utrecht. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 47, co-authored 219 publications receiving 10577 citations. Previous affiliations of Guy E.H.M. Rutten include Oklahoma State University Center for Health Sciences & Utrecht University.
Papers
More filters
Journal ArticleDOI
Attributes of clinical guidelines that influence use of guidelines in general practice: observational study
R.P.T.M. Grol,Johannes Dalhuijsen,Siep Thomas,Cees in ’t Veld,Guy E.H.M. Rutten,Henk Mokkink +5 more
TL;DR: People and organisations setting evidence based clinical practice guidelines should take into account some of the other important attributes of effective recommendations for clinical practice, including evidence based, controversial, concrete.
Journal ArticleDOI
Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.
L M A J Muller,Kees J. Gorter,Eelko Hak,W L Goudzwaard,François G. Schellevis,Andy I. M. Hoepelman,Guy E.H.M. Rutten +6 more
TL;DR: Patients with DM1 and DM2 are at increased risk for lower respiratory tract infection, urinary tract infections, and skin and mucous membrane infection, and risks increased with recurrences of common infections.
Journal ArticleDOI
Effect of valsartan on the incidence of diabetes and cardiovascular events.
John J.V. McMurray,Rury R. Holman,Steven M. Haffner,M A Bethel,Bjoern Holzhauer,Tsushung Hua,Yuri N. Belenkov,Mitradev Boolell,John B. Buse,Brendan M. Buckley,Antonio Roberto Chacra,Fu-Tien Chiang,Bernard Charbonnel,Chun Chung Chow,Melanie J. Davies,Prakash Deedwania,Peter Diem,Daniel Einhorn,Vivian Fonseca,Gregory R. Fulcher,Zbigniew Gaciong,Sonia Gaztambide,Thomas D. Giles,Edward S. Horton,Hasan Ilkova,Trond Jenssen,Steven E. Kahn,Henry Krum,Markku Laakso,Lawrence A. Leiter,Naomi S. Levitt,Viacheslav Mareev,Felipe Martinez,Chantal Masson,Theodore Mazzone,Eduardo Meaney,Richard W. Nesto,Chang-yu Pan,R. Prager,Sotirios A. Raptis,Guy E.H.M. Rutten,Herbert Sandstroem,Frank Schaper,André Scheen,Ole Schmitz,Isaac Sinay,Vladimír Soška,Steen Stender,Gyula Tamás,Gianni Tognoni,Jaakko Tuomilehto,Alberto S. Villamil,Juraj Vozar,Robert M. Califf +53 more
TL;DR: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.
Journal ArticleDOI
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
Floris A. van de Laar,Peter Lucassen,Reinier Akkermans,Eloy H. van de Lisdonk,Guy E.H.M. Rutten,Chris van Weel +5 more
TL;DR: AGIs have clear beneficial effects on glycemic control and postload insulin levels but not on plasma lipids, and there is no need for dosages higher than 50 mg acarbose t.i.d.
Journal ArticleDOI
Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes
W. Ken Redekop,Marc A. Koopmanschap,Ronald P. Stolk,Guy E.H.M. Rutten,Bruce H. R. Wolffenbuttel,Louis W. Niessen +5 more
TL;DR: Obesity and the presence of complications are important determinants of HRQOL in patients with type 2 diabetes in the Netherlands and which patient characteristics are associated with quality of life and treatment satisfaction are examined.